TrialsgrambetaRCTs are beautiful

OlympiA

2021

Adjuvant Olaparib for High-Risk gBRCA-Mutant Early Breast Cancer

In 1,836 patients with HER2-negative, high-risk early breast cancer and germline BRCA1/2 mutation, one year of adjuvant olaparib reduced invasive disease-free survival events compared with placebo.

Result

Efficacy: Invasive disease-free survivalHR 0.58

Below 1 favours adjuvant olaparib, above 1 favours placebo.

Event rates
Absolute difference
8.8 points

The absolute difference is derived from the event rates.

Also reported: 4-yr OS 89.8% vs 86.4% (HR 0.68).

Original publication
Subtopic
BRCA1/2 adjuvant
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Tutt ANJ, et al. N Engl J Med. 2021;384(25):2394-2405.doi 10.1056/NEJMoa2105215

Discussion & critique

First positive PARP-inhibitor trial in (neo)adjuvant breast cancer. Requires upfront germline BRCA testing, including in early-stage disease.